Onco Wiki / drapeau rouge

Cancer de la prostate métastatique sensible aux hormones répondant aux critères de risque élevé LATITUDE — ≥2 de...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-LATITUDE-HIGH-RISK-MHSPC
TypeSignal d’alerte
Étatreviewed 2026-04-27 | pending_clinical_signoff
MaladiesDIS-PROSTATE
SourcesSRC-EAU-PROSTATE-2024 SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025

Origine du drapeau rouge

DéfinitionMetastatic hormone-sensitive prostate cancer meeting LATITUDE high-risk criteria — ≥2 of (Gleason ≥8, ≥3 bone metastases, visceral metastases) — supports abiraterone + ADT doublet (or triplet with docetaxel where high-volume by CHAARTED also met)
Direction cliniqueintensifier
Catégoriescore de risque
Algorithme de décalageALGO-PROSTATE-MHSPC-1L

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "prostate_latitude_risk",
      "value": "high"
    },
    {
      "all_of": [
        {
          "comparator": ">=",
          "finding": "prostate_high_risk_factor_count",
          "threshold": 2
        }
      ]
    }
  ],
  "type": "composite_clinical"
}

Notes

LATITUDE (Fizazi NEJM 2017) defined high-risk as ≥2 of: Gleason ≥8, ≥3 bone mets, presence of visceral mets. The high-risk cohort showed 4-yr OS improvement with abiraterone + ADT vs ADT alone (HR 0.62). NCCN / ESMO / EAU 2024 endorse abiraterone + ADT as standard for LATITUDE high-risk. Co-fires with RF-CHAARTED-HIGH-VOLUME-MHSPC; when both fire, PEACE-1 / ARASENS data support adding docetaxel for triplet. Direction `intensify` toward ADT + ARSI (abiraterone preferred per LATITUDE; apalutamide / enzalutamide also acceptable per TITAN / ENZAMET) over ADT monotherapy. Composite trigger uses pre-computed prostate_high_risk_factor_count when available; otherwise individual factor flags can be assessed by extending the trigger schema later.

Utilisé par

Algorithmes

Signal d’alerte